1. Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis
- Author
-
Jun-Heng Bai, Xiao-Lu Ren, Wen-Wen Dong, Jie-Quan Yang, Meng-Sheng Cui, Jian-Jun Shi, and Xiao-Fei Chang
- Subjects
Oncology ,PARP, Poly-ADP-ribose polymerase ,medicine.medical_specialty ,Combination therapy ,RR, relative risk ,Poly(ADP-ribose) Polymerase Inhibitors ,Lower risk ,TNBC, triple-negative breast cancer ,OS, overall survival ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,030212 general & internal medicine ,RCT, randomized controlled trial ,RC254-282 ,business.industry ,Hazard ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,medicine.disease ,Combined Modality Therapy ,HR, hazard ratio ,Progression-Free Survival ,PFS, progression-free survival ,pCR, pathological complete response ,Confidence interval ,CI, confidence interval ,Clinical trial ,Meta-analysis ,Poly-ADP-Ribose polymerase ,030220 oncology & carcinogenesis ,Relative risk ,Female ,Original Article ,Surgery ,Breast neoplasms ,business ,AE, adverse event ,ORR, overall response rate - Abstract
Background Many breast cancer clinical trials with PARPi have been completed or are currently carried out, either by monotherapy or combined with chemotherapy. We aim to assess the efficacy and safety of PARPi in breast cancer patients as compared to chemotherapy. Methods A comprehensive literature search of PubMed, EMBASE, CENTRAL, conference meetings and clinical trial registry was performed. The primary outcomes were progression-free survival (PFS), overall survival (OS), overall response rate (ORR). The secondary outcome was safety profile. The comparative effects were measured using hazard ratio (HR) or relative risk (RR) with 95% confidence interval. Subgroup analyses were conducted based on types of intervention and baseline characteristics of patients. Results Six RCTs (n = 1953) were included. Two RCTs were recognized as high risk. PARPi was associated with an improved PFS (HR, 0.65; 95% CI, 0.56–0.74), OS (HR, 0.86; 95% CI, 0.73–1.01), and a higher ORR (RR, 1.38; 95% CI, 1.05–1.82). PARPi, however, significantly increased risk of grade 3–4 thrombocytopenia (RR, 1.63; 95% CI, 1.06–2.52). Monotherapy was observed with lower risk of disease progression and higher ORR rate than combination therapy, 0.56 to 0.65 and 2.21 to 1.05, respectively. For patients without prior platinum treatment, PARPi significantly improved PFS (HR, 0.64; 95% CI, 0.52–0.79). Conclusions PARPi was observed with a significantly improved efficacy in aspects of PFS and ORR, but also higher risk of grade 3–4 thrombocytopenia as compared to chemotherapy. PARPi was a better choice for patients who had not received previous platinum treatment., Highlights • PARPi showed improved efficacy in PFS and ORR. • PARPi presented higher risk of grade 3–4 thrombocytopenia. • PARPi is better for patients who had not received prior platinum treatment.
- Published
- 2021
- Full Text
- View/download PDF